NCT03240315 is a clinical trial in Pulmonary Disease, Chronic Obstructive, sponsored by Guangzhou Institute of Respiratory Disease.

Who is sponsoring NCT03240315?

NCT03240315 is sponsored by Guangzhou Institute of Respiratory Disease.

What condition does NCT03240315 study?

NCT03240315 studies Pulmonary Disease, Chronic Obstructive.

Is NCT03240315 still recruiting?

NCT03240315 is currently active, enrolled. Last updated 12 January 2026.

Last reviewed 2026-01-12 · How we verify

NCT03240315

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Active, enrolled Last updated 12 January 2026

What this trial tests

trial in Pulmonary Disease, Chronic Obstructive in 442 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2016

Primary endpoint
30 September 2026

30 December 2026

Quick facts

Lead sponsor	Guangzhou Institute of Respiratory Disease
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	442
Start date	1 August 2016
Primary completion	30 September 2026
Estimated completion	30 December 2026
Sites	1 location across China

Conditions studied

Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →

Sponsor

Guangzhou Institute of Respiratory Disease

Who can join

40 and older, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 3-year longitudinal study designed to establish a personalized prediction and prevention system for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Data will be prospectively collected from patients with chronic obstructive pulmonary disease (COPD) and healthy control participants, including clinical characteristics, pathophysiological parameters, etiological factors, and immunological information. These data will be analyzed using data mining approaches combined with Internet-based technologies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Association Between Airway Mucus Plugs and Risk of Moderate-to-Severe Exacerbations in Patients With COPD: Results From a Chinese Prospective Cohort Study.
Li X, Feng S, Yang Y, Liang Z, et al · · 2025 · cited 9× · PMID 40210091 · DOI 10.1016/j.chest.2025.03.026
Acute exacerbation prediction of COPD based on Auto-metric graph neural network with inspiratory and expiratory chest CT images.
Wang S, Li W, Zeng N, Xu J, et al · · 2024 · cited 6× · PMID 38601695 · DOI 10.1016/j.heliyon.2024.e28724
The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China.
He W, Li X, Huang H, Tang Z, et al · · 2026 · PMID 41761148 · DOI 10.1186/s12890-026-04171-9

Verify or expand the search:

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting

Other Guangzhou Institute of Respiratory Disease trials

Trials by the same sponsor.

NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03240315 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03240315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing